NUVB: Patient Starts Are Climbing — Tactical Long as IBTROZI Converts to Revenue
Nuvation Bio's commercial traction for IBTROZI is real — management is adding >200 new patients per quarter and revenue is accelerating — but a conversion gap and legal noise have kept the shares depressed. The balance of data supports a tactical long: buy weakness, manage downside below the recent low, and target a re-rate as conversion and guidan…